Capecitabine plus cisplatin (XP) combination chemotherapy is one of the global standard regimens as first-line for HER2-negative AGC. But in Japan, S-1 plus cisplatin (SP) combination chemotherapy is regarded as a standard regimen by SPIRITS trial. So, few data are existed for the results of XP in Japan.Methods
Thirteen AGC patients were treated XP (capecitabine 2000 mg/m2 on day 1–14, CDDP 80 mg/m2 on day 1, q3w) as first-line in clinical practice. We estimated response rate (RR), time to treatment failure (TTP), progression-free survival, overall survival (OS), and toxic effects.Results
Between December 2010 and November 2011, 13 AGC patients were treated XP in our hospital. PS0/1/2: 8/4/1, median age: 70 years old (22–80), gender: m/f: 5/8, differentiated type/undifferentiated type: 5/8. Median courses were 3 (1–6). The most common grade 3/4 adverse events were neutropenia (23%), anemia (8%), and AST elevated (8%). Two patients died within 30 days after the last administration due to disease progression. In seven patients who had measurable lesions, five patients were partial response (71%). Median PFS were 188 days and median OS was not reached.Conclusions
XP combination therapy was feasible and effective as first-line chemotherapy for AGC in clinical practice in Japan.